series-a
Stage
About
Thryv Therapeutics is a clinical-stage biotechnology company developing novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for the treatment of inherited cardiac arrhythmias, Long QT Syndrome, and cardiometabolic diseases.
Explore Thryv Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.